Sanuwave Health to Uplist to the Nasdaq Global Market
Sanuwave Health (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, has announced its approval for listing on the Nasdaq Global Market. The company's common stock will begin trading on Nasdaq on March 7, 2025, maintaining its current ticker symbol 'SNWV'.
The transition from OTCQB to Nasdaq represents a significant milestone for Sanuwave after 18 months of transition and progress. Stockholders are not required to take any action regarding the uplisting. CEO Morgan Frank expressed enthusiasm about joining one of the world's premier stock exchanges, highlighting the company's goal of transforming the wound care market and creating shareholder value.
Sanuwave Health (OTCQB: SNWV), un fornitore leader di prodotti per la cura delle ferite di nuova generazione approvati dalla FDA, ha annunciato la sua approvazione per la quotazione sul Nasdaq Global Market. Le azioni ordinarie dell'azienda inizieranno a essere scambiate su Nasdaq il 7 marzo 2025, mantenendo il simbolo di borsa attuale 'SNWV'.
Il passaggio da OTCQB a Nasdaq rappresenta una pietra miliare significativa per Sanuwave dopo 18 mesi di transizione e progresso. Gli azionisti non sono tenuti a intraprendere alcuna azione riguardo l'up-listing. Il CEO Morgan Frank ha espresso entusiasmo per l'ingresso in una delle principali borse valori del mondo, sottolineando l'obiettivo dell'azienda di trasformare il mercato della cura delle ferite e creare valore per gli azionisti.
Sanuwave Health (OTCQB: SNWV), un proveedor líder de productos de cuidado de heridas de próxima generación aprobados por la FDA, ha anunciado su aprobación para la cotización en el Nasdaq Global Market. Las acciones comunes de la empresa comenzarán a cotizar en Nasdaq el 7 de marzo de 2025, manteniendo su símbolo de cotización actual 'SNWV'.
La transición de OTCQB a Nasdaq representa un hito significativo para Sanuwave después de 18 meses de transición y progreso. Los accionistas no necesitan tomar ninguna acción respecto a la uplisting. El CEO Morgan Frank expresó su entusiasmo por unirse a una de las principales bolsas de valores del mundo, destacando el objetivo de la empresa de transformar el mercado de cuidado de heridas y crear valor para los accionistas.
사누웨이브 헬스 (OTCQB: SNWV)는 FDA 승인 차세대 상처 치료 제품의 선도적인 공급업체로서 나스닥 글로벌 마켓 상장 승인을 발표했습니다. 회사의 보통주는 2025년 3월 7일에 나스닥에서 거래를 시작하며, 현재의 티커 기호 'SNWV'를 유지합니다.
OTCQB에서 나스닥으로의 전환은 사누웨이브에게 18개월의 전환과 발전을 거친 중요한 이정표를 나타냅니다. 주주들은 업리스트와 관련하여 어떤 조치를 취할 필요가 없습니다. CEO 모건 프랭크는 세계 최고의 증권 거래소 중 하나에 합류하게 된 것에 대한 열정을 표현하며, 상처 치료 시장을 변화시키고 주주 가치를 창출하는 회사의 목표를 강조했습니다.
Sanuwave Health (OTCQB: SNWV), un fournisseur de premier plan de produits de soins des plaies de nouvelle génération approuvés par la FDA, a annoncé son approbation pour une cotation sur le Nasdaq Global Market. Les actions ordinaires de l'entreprise commenceront à être échangées sur le Nasdaq le 7 mars 2025, tout en conservant son symbole boursier actuel 'SNWV'.
La transition de l'OTCQB au Nasdaq représente une étape significative pour Sanuwave après 18 mois de transition et de progrès. Les actionnaires n'ont pas besoin de prendre de mesures concernant l'up-listing. Le PDG Morgan Frank a exprimé son enthousiasme à l'idée de rejoindre l'une des principales bourses mondiales, soulignant l'objectif de l'entreprise de transformer le marché des soins des plaies et de créer de la valeur pour les actionnaires.
Sanuwave Health (OTCQB: SNWV), ein führender Anbieter von FDA-zugelassenen Wundversorgungsprodukten der nächsten Generation, hat seine Genehmigung zur Notierung an der Nasdaq Global Market bekannt gegeben. Die Stammaktien des Unternehmens werden am 7. März 2025 an der Nasdaq gehandelt, wobei das aktuelle Tickersymbol 'SNWV' beibehalten wird.
Der Übergang von OTCQB zu Nasdaq stellt einen bedeutenden Meilenstein für Sanuwave nach 18 Monaten des Wandels und Fortschritts dar. Aktionäre müssen keine Maßnahmen bezüglich der Uplisting ergreifen. CEO Morgan Frank äußerte seine Begeisterung über den Beitritt zu einer der weltweit führenden Börsen und hob das Ziel des Unternehmens hervor, den Wundversorgungsmarkt zu transformieren und den Aktionärswert zu steigern.
- Uplisting from OTCQB to Nasdaq Global Market
- Enhanced visibility and potential trading liquidity through Nasdaq listing
- No dilutive action required from shareholders for uplisting
- None.
Trading Under the Ticker “SNWV” Expected to Begin on March 7, 2025
EDEN PRAIRIE, Minn., March 04, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the “Company” or "Sanuwave”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, announced today that its common stock has been approved for listing on the Nasdaq Global Market (“Nasdaq”).
Trading on Nasdaq is expected to commence at the market open on March 7, 2025, with shares continuing to trade under the ticker symbol “SNWV.” The Company’s shares will trade on the OTCQB until trading on Nasdaq commences. Stockholders are not required to take any action as a result of the uplisting.
Commenting on the announcement, CEO Morgan Frank stated, “The last 18 months have been a time of transition and progress at Sanuwave, and it’s with great excitement and pride that we join the Nasdaq Global Market, one of the premier stock exchanges in the world, as the next step toward achieving our aim of transforming the wound care market and driving value for our shareholders. This is going to be fun.”
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates helps restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to the timing of the planned uplisting to Nasdaq, future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ
When will Sanuwave Health (SNWV) start trading on the Nasdaq Global Market?
What actions do Sanuwave Health (SNWV) shareholders need to take for the Nasdaq uplisting?
What is Sanuwave Health's (SNWV) current trading market before the Nasdaq uplisting?
Will Sanuwave Health (SNWV) change its ticker symbol when listing on Nasdaq?
